



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit [go.covermymeds.com/OptumRx](http://go.covermymeds.com/OptumRx) to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

## Lynparza<sup>®</sup> Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting <b>brand</b>			Directions for Use:		
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>					
Clinical Information (required)					
<b>Select the diagnosis below:</b>					
<input type="checkbox"/> Breast cancer					
<input type="checkbox"/> Ovarian cancer					
<input type="checkbox"/> Epithelial ovarian cancer					
<input type="checkbox"/> Fallopian tube cancer					
<input type="checkbox"/> Primary peritoneal cancer					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
<b>Clinical Information:</b>					
Is Lynparza prescribed by or in consultation with an oncologist? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is this request for continuation of prior Lynparza therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient been on Lynparza within the past 120 days? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is there presence of deleterious or suspected deleterious germline BRCA-mutations as detected by an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>For breast cancer, answer the following:</b>					
Does the patient have metastatic disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Does the patient have recurrent disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Does the patient have human epidermal growth factor receptor 2 (HER2)-negative disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient been previously treated with chemotherapy (e.g., anthracycline, taxane) in the neoadjuvant, adjuvant, or metastatic setting? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Does the patient have hormone receptor (HR)-positive disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient experienced disease progression on prior endocrine therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is there provider attestation that endocrine therapy is inappropriate for the patient's disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>For ovarian cancer, answer the following:</b>					
Select if the patient has the following disease characteristics:					
<input type="checkbox"/> Advanced					
<input type="checkbox"/> Persistent					
<input type="checkbox"/> Recurrent					
Does the patient have trial and failure, contraindication, or intolerance to three or more prior lines of chemotherapy (e.g., paclitaxel with cisplatin)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is Lynparza used for maintenance treatment in patients who have had complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin)? <input type="checkbox"/> Yes <input type="checkbox"/> No					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Lynparza\_CMS\_2019Jan-W



## Lynparza<sup>®</sup> Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

### Quantity limit requests:

What is the quantity requested per MONTH? \_\_\_\_\_

### What is the reason for exceeding the plan limitations?

- Titration or loading-dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- There is a medically necessary justification why the patient cannot use a higher commercially available strength to achieve the same dosage and remain within the same dosing frequency. **Please specify:** \_\_\_\_\_
- Other: \_\_\_\_\_

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

---

### Please note:

This request may be denied unless all required information is received.

If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.

For urgent or expedited requests please call 1-800-711-4555.

This form may be used for non-urgent requests and faxed to 1-800-527-0531.